SEPN - Septerna, Inc. Common Stock

SEPN - Septerna, Inc. Common Stock

https://septerna.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Septerna ( NASDAQ:SEPN )

Benzinga • 2 months, 3 weeks ago • score: 0.23

HC Wainwright gives Septerna a Buy rating and $26 price target citing multiple upcoming catalysts. Septerna trades below cash value despite a Novo Nordisk partnership and a promising drug pipeline. Get access to the leaderboards pointing to tomorrow's biggest stock movers.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$28.99

52W Low

$4.17

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

136.40

P/S (TTM) (<3 favorable)

454.70

P/B (<3 favorable)

1.11

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.74%

Institutions (25–75% balanced)

102.92%

Shares Outstanding

44,558,300

Float

18,175,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

977,000

Gross Profit (TTM)

977,000

EPS (TTM)

-1.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-118.31%

ROE (TTM) (>15% strong)

-0.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.31

Momentum

Bearish momentum

Value

0.9083

Previous

0.9464

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025